Research Article

Drug Resistance Mechanisms of *Mycoplasma pneumoniae* to Macrolide Antibiotics

Xijie Liu, Yue Jiang, Xiaogeng Chen, Jing Li, Dawei Shi, and Deli Xin

1 Pediatric Apartment, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2 Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing 100050, China

Correspondence should be addressed to Deli Xin; xindl48@126.com

Received 1 May 2013; Accepted 16 December 2013; Published 28 January 2014

Academic Editor: Atsushi Harimaya

Copyright © 2014 Xijie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Throat swabs from children with suspected *Mycoplasma pneumoniae* (*M. pneumoniae*) infection were cultured for the presence of *M. pneumoniae* and its species specificity using the 16S rRNA gene. Seventy-six *M. pneumoniae* strains isolated from 580 swabs showed that 70 were erythromycin resistant with minimum inhibitory concentrations (MIC) around 32–512 mg/L. Fifty *M. pneumoniae* strains (46 resistant, 4 sensitive) were tested for sensitivity to tetracycline, ciprofloxacin, and gentamicin. Tetracycline and ciprofloxacin had some effect, and gentamicin had an effect on the majority of *M. pneumoniae* strains. Domains II and V of the 23S rRNA gene and the ribosomal protein L4 and L22 genes, both of which are considered to be associated with macrolide resistance, were sequenced and the sequences were compared with the corresponding sequences in M129 registered with NCBI and the FH strain. The 70 resistant strains all showed a 2063 or 2064 site mutation in domain V of the 23S rRNA but no mutations in domain II. Site mutations of L4 or L22 can be observed in either resistant or sensitive strains, although it is not known whether this is associated with drug resistance.

1. Introduction

*Mycoplasma pneumoniae* is a common pathogen of respiratory tract infection in children and adolescents and can cause serious pneumonia and external lung complications [1]. At present, the preferred treatment is macrolide antibiotics. In recent years, however, many countries have reported the isolation of clinically drug-resistant strains [2–5], the main mechanism of resistance being a mutation in the 23S rRNA gene which is the target of macrolide antibiotic action [6, 7]. In China, there are a number of reports of clinically resistant *M. pneumoniae* strains [8, 9], resulting in serious failure of effective antibacterial agents. In this study macrolide-resistant *M. pneumoniae* strains isolated between 2003 and 2007 were screened for sensitivity to antibacterial activity of tetracycline, ciprofloxacin, and gentamicin. The strains were typed for domain II and V of 23S rRNA, and for the ribosomal protein L4 and L22 genes, which are also associated with macrolide resistance.

2. Materials and Methods

2.1. Isolation, Culture, and Identification of *M. pneumoniae*

2.1.1. Specimens. 580 cases of throat swab specimens were collected from the suspected *M. pneumoniae* infected children (age range: 1–14) in the pediatric wards of Beijing Friendship Hospital affiliated to the Capital University of Medical Sciences.

2.1.2. *M. pneumoniae* Culture Medium. PPLO basic medium was used containing 15% newborn calf serum, 10% fresh yeast extract, 0.4% phenol red indicator, 1% glucose, and 50000 U/100 mL penicillin.

2.1.3. Culture and Identification. The throat swab specimens were inoculated in *M. pneumoniae* liquid medium, mixed evenly, and placed in an incubator at 37°C, with 5% CO₂ for cultivation. Growth of *M. pneumoniae* causes decrease
of PH of the medium, which is indicated by a color change (from red to yellow) in the indicator. Nested PCR for species-specific *M. pneumoniae* identification was carried out on all positive samples using primers for the 16S rRNA gene [2].

2.2. In Vitro Drug Sensitivity Test. Equal volumes of *M. pneumoniae* bacteria fluid (concentration: 10^5 CCU/mL) and drug (diluted to the desired concentrations with *M. pneumoniae* medium) were incubated in an incubator at 37°C, with 5% CO₂. Color change of the medium was used to estimate the minimum drug concentration that could inhibit *M. pneumoniae* growth (MIC). Erythromycin, tetracycline, ciprofloxacin, and gentamicin were all purchased from the National Institute for the Control of Pharmaceutical and Biological Products.

2.3. Analysis of Domains II and V of 23S rRNA Gene and the Ribosomal Protein L4 and L22 Genes

2.3.1. DNA Extraction. 20 μL *M. pneumoniae* bacteria fluid was collected, centrifuged at 12000 r/min for 10 min, and the supernatant was removed. 200 μL 1% Triton X-100 was added to the pellet, mixed evenly, and placed in a boiling water bath for 10 min.

2.3.2. PCR Amplification and DNA Sequencing. The primers for amplification of a 793 fragment of domain V of the 23S rRNA gene were designed (P3 5'-TAACTATAACGGTTAAGG-3' and P4 5'-CGCTACAACGGGAGCATAAG-3'); primers for domain II of 23S rRNA and for L4 and L22 were as reported by Waites and Talkington [1] (see Table 1). The PCR mixture for domain II of 23S rRNA with L4 and L22 contained 15 pmol in each of forward and reverse primers, 1U TaqDNA polymerase, 20 μL total reaction volume, and 5 μL DNA template. PCR conditions were initial denaturation for 2 min at 94°C, followed by 94°C for 45 s, 55°C for 1 min, 72°C for 30 cycles, and a final 5 min extension cycle at 72°C. The specific nested PCR method for domain V of 23S rRNA was as described in [2]. The amplified products were purified and subjected to full-auto DNA sequencing (ABI 3730XL sequenator from Shanghai Sangon Biological Technologies & Service Co., Ltd.). Resulting sequences were compared with the corresponding sequences of the standard strain M129 registered at NCBI.

### Table 1: Primer sequences and target fragment length of PCR amplification.

| Primer name         | Primer sequence (5'-3')                             | Target fragment |
|---------------------|-----------------------------------------------------|-----------------|
| 23S rRNA II zone    | Forward: AGTACCGTGAGGAAAGGTG<br>Reverse: TCCCAAGCGTTACTATGCC | 816 bp          |
| Ribosomal protein L4| Forward: AAAAGCACGACAGTTGTAG<br>Reverse: GGTAGAAGCTGTGTTTAGCA | 722 bp          |
| Ribosomal protein L22| Forward: GTACATAACGGCAAGCCTT<br>Reverse: GCAAGCGTTGGAGTTTACT  | 627 bp          |
| 23S rRNA V zone     | External P1: GCAGTGAAGAAGACGAGGG<br>P2: CACACTTATGCTTTCAGCG | 1012 bp         |

3. Results

3.1. *M. pneumoniae Culture and Identification.* 76 *M. pneumoniae* strains were isolated from 580 cases of throat swab specimens, and all 76 strains and the FH strain showed the same species-specific 417 bp *M. pneumoniae* fragment of the 16S rRNA gene typical of the species.

3.2. Antibiotic Sensitivity Tests

3.2.1. Erythromycin MIC. Among the 76 *M. pneumoniae* strains, 70 showed erythromycin resistance, with a significantly higher erythromycin MIC around 32–512 mg/L.

3.2.2. MICs of Tetracycline, Ciprofloxacin, and Gentamicin. The in vitro drug sensitivity tests of these three drugs were performed on 50 strains, 46 of which were erythromycin resistant and 4 erythromycin sensitive.

*The Tetracycline MIC of the Standard Strain FH Was 2 mg/L.* The MICs of the 50 isolated *M. pneumoniae* strains was between 0.5 and 2 mg/L, all within the sensitive range.

*The Ciprofloxacin MIC of the Standard Strain FH Was 1 mg/L.* The MICs of the 50 isolated *M. pneumoniae* strains was between 1 and 2 mg/L, most being within the sensitive range, only 5 *M. pneumoniae* strains showing MICs slightly higher than that of the standard strain.

*The Gentamicin MIC of the Standard Strain FH Was 4 mg/L.* The MICs of the 50 isolated *M. pneumoniae* strains was between 2 and 16 mg/L, 33 samples being within the sensitive range, the remaining 17 being higher than that of the standard strain.

The categorization of sensitivity or resistance according to the MIC values of erythromycin, tetracycline, ciprofloxacin, and gentamicin follows the standard formulated by NCCLS in 2006 [10].

3.3. PCR Amplification and DNA Sequencing. Electrophoreograms of the four PCR products of genes targeted in this study are shown in Figures 1, 2, 3, and 4 (note: M represents the standard band, FH represents MP standard strain, N is the negative control, and digits refer to the strain number). DNA sequencing results are shown in Table 2.
Table 2: Sequencing results of a part of clinically isolated strains.

| Specimen number | Ribosomal protein L4 | Ribosomal protein L22 | 23S ribosomal RNA |
|-----------------|----------------------|-----------------------|------------------|
|                 | Specimen number | 58 | 66 | 81 | 140 | 162 | 209 | 430 | 62 | 65 | 279 | 508 | Domain II | Domain V |
| N129            | C | T | G | A | C | A | A | C | T | T | T | — | — |
| FH              | — | — | — | — | C→A | — | A→G | — | — | T→C | T→C | — | — |
| 1               | — | — | — | — | C→A | — | A→G | — | — | T→C | T→C | — | A2064G |
| 19              | — | — | — | — | C→A | — | A→G | — | — | T→C | T→C | — | A2064G |
| 75              | — | — | G→T | — | — | — | — | — | — | — | — | — | — | A2064G |
| 147             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 216             | — | — | — | — | C→A | — | — | — | — | — | — | — | A2063G |
| 221             | — | T→G | — | — | — | — | — | — | — | — | — | — | A2063G |
| 223             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 246             | C→A | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 255             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 262             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 277             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 340             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 355             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| 371             | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| MEN20           | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| MEN29           | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |
| MEN30           | — | — | — | — | — | — | — | — | — | — | — | — | A2063G |

Note: — represented no base mutation by comparing with the corresponding sequences of M129 that NCBI has registered; 1, 19, 75, 147, 216, 221, 223, 246, 255, 262, 277, 340, and 355 were all clinically isolated resistant strains, while 371, MEN20, MEN29, and MEN30 were the sensitive strains. M129 and FH were the standard strains and MP gene sequences registered in NCBI gene bank were based on M129.

Domain V of 23S rRNA. 46 of the 50 previously cultured strains tested were resistant [II], and 40 of these strains showed the A2063G mutation, one strain showed an A2063C mutation, and five showed an A2064G mutation. Of the 26 recently cultured *M. pneumoniae* strains, 24 were resistant strains and they all showed the A2063G mutation. Six sensitive strains and the standard strain FH showed no mutations in this domain (Figures 5, 6, 7, and 8) (note: the part with a red underline in Figure 5 refers to the bases in the target sites 2063, 2064, and 2065 of the standard strain FH’s 23S rRNA acted by erythromycin, all were A; Figure 6 represents 2063
site's base mutation $A \rightarrow G$; Figure 7 represented 2063 site's base mutation $A \rightarrow C$; Figure 8 represented 2064 site's base mutation $A \rightarrow G$).

**Domain II of 23S rRNA.** 76 isolated *M. pneumoniae* strains and the standard strain FH showed no gene mutation in domain II of 23S rRNA.

**Ribosomal Protein L4.** Of the 76 strains, 68 showed L4 gene fragments that were identical to M129, five strains and the standard strain FH showed C162A and/or A430G mutations, and five strains each showed one mutation in another site, namely C58A, T66G, G81T, A140C, and A209T.

**Ribosomal Protein L22.** With the exception of M129, all 76 isolated strains and the standard strain FH showed the T508C mutation. Five strains plus the standard FH strain also showed a T279C mutation and eight showed C62A and/or a T65A mutation.

Blast (http://blast.ncbi.nlm.nih.gov/) was used to detect the changes of amino acids encoded by the gene mutations of ribosomal proteins L4 and L22 (Table 3).

### 4. Discussion

The emergence of drug resistant *M. pneumoniae* strains is seriously reducing the effectiveness of macrolide drugs and affecting clinical outcome of *M. pneumoniae* infection in children [2, 7]. Before the year 2000, very few macrolide-resistant *M. pneumoniae* strains were isolated [7]. By contrast, since 2001, macrolide-resistant *M. pneumoniae* isolates were first reported by Japan [10], the frequency of macrolide-resistant *M. pneumoniae* cases has increased annually in Japan: 5.0% in 2003, 30.6% in 2006, 59.1% in 2009, and 89.5% in 2011 [12]. Similarly, since our team firstly reported the appearance of resistant strains of *M. pneumoniae* in 2005 [13], the frequency of macrolide-resistant *M. pneumoniae* remained high in China, ranging from 84.4% to 100% (not published) in our lab as well as in other Chinese researchers [9, 14]. In France, Pereyre et al. reported the emergence of *M. pneumoniae* drug resistant strains; only 2 of 155 showed resistance to macrolide isolated between 1994 and 2006 [11] but risen to 10% between 2005 and 2007 reported by Peuchant et al. [15]. In the other countries, the results were as follows: In USA, the frequency of macrolide-resistant *M. pneumoniae* was 8.2% during 2007 and 2010 [16], and in Italy that was 11 out of 43 in 2010 [17]; in Germany, 2 of 167 throat swabs were macrolide resistant collected between 2003 and 2008, reported by Dumke et al. in 2010, while during 1991 and 2009, only 3 of 99 isolation showed resistance [6], and so on. In conclusion, *M. pneumoniae* shows high resistance to macrolide antibiotics, especially in Asian, and it is rising annually, which should be taken into consideration by the world.

Macrolide antibiotics act by inhibiting bacterial protein synthesis. Studies have found that the target site for macrolide
Table 3: Amino acid changes of ribosomal proteins L4 and L22.

| Specimen number | L4   | L22   | 23S rRNA domain V |
|-----------------|------|-------|-------------------|
| 75              | K27N | —     | A2064G            |
| 147             | —    | P21Q  | A2063G            |
| 216             | —    | L22Q  | A2063G            |
| 221             | —    | —     | A2063G            |
| 223             | —    | P21Q, L22Q | A2063G |
| 246             | L201 | —     | A2063G            |
| 255             | —    | L22Q  | A2063G            |
| 262             | —    | P21Q, L22Q | A2063G |
| 277             | —    | P21Q, L22Q | A2063G |
| 340             | —    | L22Q  | A2063G            |
| 355             | —    | —     | A2063G            |
| 371             | H70L | —     | —                 |
| 30              | Q47P | —     | —                 |

Note: — represented no change by comparing with the corresponding sequences of M129 that NCBI has registered. MP gene sequences registered in NCBI genebank were based on M129.

is the large (50S) subunit of the bacterial ribosome. Alterations in specific nucleotides within the 23S rRNA lead to decreased affinity between drug and ribosome. Many cases of macrolide resistance in clinical strains can be linked to mutations in the sites 2063, 2064, 2067, and 2617 in domain V of 23S rRNA [2, 7, 18]. In China, resistant strains have shown the 2063 and 2064 mutations but no mutations in any other sites [8, 9].

Ribosomal proteins L4 and L22 are also associated with drug resistance. These large subunit proteins have an elongated “tentacle” structure extending to the core of the large subunits to form the partial inner wall of the peptide output channel. Mutations within this structure can obstruct the channel and affect the binding of macrolide antibiotics [19]. In 2004, Pereyre et al. reported that amino acid changes of ribosomal proteins L4 and L22 could be induced in vitro appearing as H70R or H70L replacement, and 1–3 G insertion in site 60 in L4 as well as P112R and A114T replacement or 111IPRA114 deletion in L22 [20]. However, no mutations were found in domain II of 23S rRNA in this study and it is not known whether the mutations induced in vitro arise in clinical samples [20].

In this study, among 76 clinical M. pneumoniae strains, 70 resistant strains were found showing A2063G, A2063C, and A2064G in domain V of 23S rRNA. None of the strains had any mutations in domain II of 23S rRNA. In addition to these major mutations, some of the strains showed C58A, T66G, G81T, A140C, and A209T mutations of L4, and C62A and T65A mutations of L22, further causing the changes of encoded amino acids. Whether there was a relationship between drug resistance and these mutations will require further study. C62A site mutation of ribosomal protein L22 was also observed in the erythromycin-induced strains, suggesting that there would be the possibility of inducing resistant strains in vivo during the process of using macrolide antibiotics.

Compared with M129, some strains, including the standard FH strain, showed C162A and A430G mutations of L4 and T279C and T508C mutations of L22 (Table 2). These were associated with two types of M. pneumoniae strains classified according to the difference in PI gene, M129 being typical of PI-I type, and FH typical of PI-II type [21]. These mutations were therefore considered to be independent of M. pneumoniae drug resistance to macrolide. However, all the strains including the FH showed the T508C mutation in L22, and the PI gene is considered to be independent of M. pneumoniae resistance to macrolide. T66G mutation in the ribosomal protein L4 of strain number 221 was synonymous and considered to be unrelated to drug resistance. A140C mutation in L4 of the MEN30 strain causes a Q47P change, but as MEN30 is a sensitive strain, it is inferred that this change is independent of resistance to macrolide. The A209T mutation in the ribosomal protein L4 of number 371 strain causes a H70L change. Pereyre et al. reported in 2004 that the telithromycin-induced M. pneumoniae resistant strain (T32) also showed a H70L change in L4, the mutation of C2617A in 23S rRNA domain V, and a A114T change in L22 [20]. Meanwhile, strain No. 371, a sensitive strain, showed a 2617 site mutation in 23S rRNA domain’s zone V which is directly related to drug resistance as well as to changes in L4. Therefore, it is thought that the H70L change in L4 is unlikely to be related to drug resistance, although this needs further investigation. The remaining strains showed C58A and G81T site mutations in L4 as well as C62A and T65A site mutations in L22. Although both cause amino acid changes, but they also have the 2063 or 2064 mutation in the 23S rRNA domain V which is directly related to macrolide resistance (Table 2). Further study is needed to ascertain whether these mutations are associated with drug resistance. In this study, some of the clinically isolated strains showed a C62A mutation in the ribosomal protein L22 also found by Matsuoka et al. in Japan [22], suggesting that the use of macrolide drugs is likely to induce M. pneumoniae resistant strains.

In vitro drug sensitivity tests proved that the majority of children from whom the specimens were collected were harboring macrolide-resistant M. pneumoniae resistant strains.
Some of the infection in these children could be controlled with macrolide antibiotics, mainly because macrolide antibiotics have an antimicrobial effect in vivo and are also involved in immune regulation during the recovery process of the disease, giving some clinical effectiveness [22]. At the same time, \textit{M. pneumoniae} pneumonia is considered to be a self-limiting disease. In this study, all specimens were collected from children in the wards, and most of them had been exposed to macrolide antibiotics before sampling. Sensitive bacteria would have been inhibited, and total bacterial load reduced. This obviously made it difficult to estimate the actual levels of resistance found in our patients. However, resistant \textit{M. pneumoniae} was obviously present and suggests the necessity to be very vigilant in monitoring the phenomenon of \textit{M. pneumoniae} resistance to macrolide antibiotics.

In this study, \textit{in vitro} drug sensitivity tests were used to determine the antibacterial activities of tetracycline, ciprofloxacin, and gentamicin against \textit{M. pneumoniae}. Tetracycline mainly inhibits bacterial protein synthesis, by binding the ribosomal 30S subunits and blocking the extension or hindering the release of the protein synthesized peptide chain. Ciprofloxacin acts on \textit{M. pneumoniae} primarily through inhibition of its DNA gyrase, thus affecting DNA replication, transcription, and expression. Gentamicin is a type of aminoglycoside antibiotic that acts on ribosomal 30S subunits in bacteria, inhibiting the protein synthesis and damaging the integrity of the cell membrane, but it has a limited inhibitory effect on \textit{M. pneumoniae}. In this study, we found that 2063 and 2064 mutations in domain V of 23S rRNA of 50S subunits did not affect the binding of tetracycline, ciprofloxacin, and gentamicin with \textit{M. pneumoniae} and did not give rise to \textit{M. pneumoniae} resistance to these drugs. The results showed that tetracycline and ciprofloxacin were generally effective on \textit{M. pneumoniae}, and gentamicin was effective on the majority of \textit{M. pneumoniae} strains, although it did have poor antibacterial activity against some of the \textit{M. pneumoniae} strains.

Because there is a risk of adverse reactions with tetracycline, and the safety of ciprofloxacin patients below the age of 18 has not yet been established, neither of these drugs is suitable for use in children. Current research should therefore be focused on finding new tetracycline or quinolone drugs with a strong antibacterial activity but low side effects, so as to provide effective alternative choice of drugs for the treatment of resistant \textit{M. pneumoniae} infections.

In summary, 76 \textit{M. pneumoniae} strains were isolated and cultured, 70 of which were macrolide-resistant, being highly resistant to erythromycin and showing the 2063 and 2064 mutations in domain V of 23S rRNA which are the main genetic markers of drug resistance. The clinical \textit{M. pneumoniae} strains and erythromycin \textit{in vitro} induced \textit{M. pneumoniae} resistant strains showed gene mutations in the same sites of the ribosomal protein L22, suggesting the possibility of inducing \textit{M. pneumoniae} resistant strains \textit{in vivo} during the use of macrolide drugs. These results indicate the importance of continued research on the resistance mechanisms of drug resistance and in particular an increased urgency in finding effective new antibacterial drugs suitable for treating \textit{M. pneumoniae} in children.

**Conflict of Interests**

The authors declare that they have no conflict of interests in relation to this work.

**Authors’ Contribution**

Xijie Liu and Yue Jiang contributed equally to this work.

**References**

[1] K. B. Waite and D. F. Talkington, “\textit{Mycoplasma pneumoniae} and its role as a human pathogen,” \textit{Clinical Microbiology Reviews}, vol. 17, no. 4, pp. 697–728, 2004.

[2] M. Morozumi, T. Takahashi, and K. Ubukata, “Macrolide-resistant \textit{Mycoplasma pneumoniae}: characteristics of isolates and clinical aspects of community-acquired pneumonia;” \textit{Journal of Infection and Chemotherapy}, vol. 16, no. 2, pp. 78–86, 2010.

[3] A. Lenglet, Z. Herrador, A. P. Magiorakos, K. Leitmeyer, and D. Coulombier, “Surveillance status and recent data for \textit{Mycoplasma pneumoniae} infections in the European union and European Economic Area, January 2012,” \textit{Eurosurveillance}, vol. 17, no. 5, 2012.

[4] D. Averbuch, C. Hidalgo-Grass, A. E. Moses, D. Engelhard, and R. Nir-Paz, “Macrolide resistance in \textit{Mycoplasma pneumoniae}, Israel, 2010,” \textit{Emerging Infectious Diseases}, vol. 17, no. 6, pp. 1079–1082, 2011.

[5] E. Jacobs, “\textit{Mycoplasma pneumoniae}: now in the focus of clinicians and epidemiologists,” \textit{Eurosurveillance}, vol. 17, no. 6, 2012.

[6] H. von Baum, P. C. Lück, and E. Jacobs, “Occurrence of macrolide-resistant \textit{Mycoplasma pneumoniae} strains in Germany,” \textit{Clinical Microbiology and Infection}, vol. 16, no. 6, pp. 613–616, 2010.

[7] C. Bébèar, S. Pereyre, and O. Peuchant, “\textit{Mycoplasma pneumoniae} susceptibility and resistance to antibiotics;” \textit{Future Microbiology}, vol. 6, no. 4, pp. 423–431, 2011.

[8] D. Xin, Z. Mi, X. Han et al., “Molecular mechanisms of macrolide resistance in clinical isolates of \textit{Mycoplasma pneumoniae} from China,” \textit{Antimicrobial Agents and Chemotherapy}, vol. 53, no. 5, pp. 2158–2159, 2009.

[9] F. Zhao, G. Liu, J. Wu et al., “Surveillance of macrolide-resistant \textit{Mycoplasma pneumoniae} in Beijing, China, from 2008 to 2012,” \textit{Antimicrob Agents Chemother}, vol. 57, no. 3, pp. 1521–1523, 2013.

[10] N. Okazaki, M. Narita, S. Yamada et al., “Characteristics of macrolide-resistant \textit{Mycoplasma pneumoniae} strains isolated from patients and induced with erythromycin \textit{In Vitro},” \textit{Journal of Clinical Microbiology}, vol. 45, no. 8, pp. 617–620, 2001.

[11] S. Pereyre, A. Charron, H. Renaudin, C. Bébèar, and C. M. Bébèar, “First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in \textit{Mycoplasma pneumoniae} clinical strains isolated in France over 12 years,” \textit{Clinical Microbiology Reviews}, vol. 45, no. 11, pp. 3534–3539, 2007.

[12] Y. Suzuki, T. Itagaki, J. Seto et al., “Community outbreak of macrolide-resistant \textit{Mycoplasma pneumoniae} in Yamagata, Japan in 2009;” \textit{The Pediatric Infectious Disease Journal}, vol. 32, no. 3, pp. 237–240, 2013.

[13] D.-L. Xin, Z.-H. Mi, A.-C. Hou et al., “Molecular mechanisms of erythromycin resistance in \textit{Mycoplasma pneumoniae},” \textit{Journal of Applied Clinical Pediatrics}, vol. 20, no. 7, pp. 666–667, 2005.
[14] Y. Liu, X. Ye, H. Zhang et al., “Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China,” *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 5, pp. 2160–2162, 2009.

[15] O. Peuchant, A. Ménard, H. Renaudin et al., “Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis,” *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 1, pp. 52–58, 2009.

[16] B. J. Wolff, W. L. Thacker, S. B. Schwartz, and J. M. Winchell, “Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis,” *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 10, pp. 3542–3549, 2008.

[17] M. Chironna, A. Sallustio, S. Esposito et al., “Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children,” *Journal of Antimicrobial Chemotherapy*, vol. 66, no. 4, pp. 734–737, 2011.

[18] N. Principi and S. Esposito, “Macrolide-resistant Mycoplasma pneumoniae its role in respiratory infection,” *Journal of Antimicrobial Chemotherapy*, vol. 68, no. 3, pp. 506–511, 2013.

[19] S. Zaman, M. Fitzpatrick, L. Lindahl, and J. Zengel, “Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in *Escherichia coli*,” *Molecular Microbiology*, vol. 66, no. 4, pp. 1039–1050, 2007.

[20] S. Pereyre, C. Guyot, H. Renaudin, A. Charron, C. Bébéar, and C. M. Bébéar, “In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae in Vitro,” *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 2, pp. 460–465, 2004.

[21] X.-J. Tian, Y.-Q. Dong, X.-P. Dong et al., “P1 gene of *Mycoplasma pneumoniae* in clinical isolates collected in Beijing in 2010 and relationship between genotyping and macrolide resistance,” *Chinese Medical Journal*, vol. 126, no. 20, pp. 3944–3948, 2013.

[22] M. Matsuoka, M. Narita, N. Okazaki et al., “Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan,” *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 12, pp. 4624–4630, 2004.